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Abstract
Severe traumatic brain injury (TBI) is currently managed in the intensive care unit (ICU) by a combined
medical-surgical approach. Treatment aims to prevent additional brain damage and to optimize conditions for
brain recovery. TBI is considered and treated as a single pathological entity, though in fact it is a syndrome,
comprising a range of lesions, which may demand different therapies and physiological goals. Thanks to
advances in monitoring and imaging, there is now the potential to identify specific mechanisms of brain
damage and to better target treatment to individual patients or subsets of patients. This is particularly relevant
to elderly subjects, as TBI now affects an increasing proportion of aged patients. Pre-injury comorbidities
and their therapies demand specific treatment, with strategies tailored to older cases. Advances in monitoring
and  in  pathophysiological  understanding  may  change  the  current  ICU  management  with  targeted
interventions, ultimately improving outcome.
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Introduction
Traumatic brain injury (TBI) is a major cause of death and disability worldwide, with more than 13 million
people estimated to live with disabilities related to TBI in Europe and the USA1. Approximately 10–15% of
patients with TBI have serious injuries that require specialist care2.  Severe grades of TBI are commonly
managed  in  the  intensive  care  unit  (ICU)3 based  on  a  combined medical-surgical  approach,  which  has
changed little over the last 20 years. A reassessment of this area of clinical practice is warranted on several
grounds.  First, recent expert reappraisals of such care have indicated that the evidence supporting most of
our interventions is weak or non-existent4, with few randomized controlled trials (RCTs) to guide treatment
decisions. Given this dearth of evidence-based medicine to underpin clinical care, clinicians have had to rely
on  best  practice  statements  from  expert  bodies,  based  on  decades  of  accumulated  and  refined  clinical
experience5. Moreover, treatment targets incorporated into guidelines are usually derived from population
studies  and  applied  to  the  entire  ICU population  of  TBI  patients . This  approach  reduces  management
variability, but ignores differences in the underlying pathology. TBI is in fact a syndrome that includes a
range of brain lesions, with separate, sometimes diverging, pathophysiological paths and therapeutic needs.
Consequently, undifferentiated interventions aimed at  the overall  population of TBI patients,  rather than
targeted to specific disease mechanisms and patient groups, are likely to fail, as exemplified by repeated
failures of clinical trials of neuroprotective agents6. 
Furthermore, many patients with TBI now treated in the ICU are significantly different from those on which
our accumulated clinical experience, research, and guidelines derives – young (typically male) patients who
sustained a TBI from high-velocity traffic injuries or assault.  In high-income countries (HICs), TBI affects
increasing proportions of people older than 65 years (that we arbitrarily indicate as elderly): e.g., in the USA,
the rate of TBI-related hospitalization for elderly people has increased by more than 50% from 2001 to
20107. This epidemiological change reflects increased life expectancy8 coupled with new risk factors typical
of  the  elderly,  such  as  anticoagulant  medications.  These  older  patients  typically  present  after  having
sustained falls from a relatively low height, and have the clinical course of their TBI complicated by multiple
comorbidities and their treatment. 
This manuscript briefly reviews the heterogeneity of the pathology and pathophysiology of TBI seen in the
ICU, explores how we might organize rational clinical care in view of the scarcity of conventional evidence
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from RCTs, and how we might individualize care to aim for precision medicine approaches, considering
pathophysiological diversity with use of advances monitoring techniques. We focus on severe TBI in adults,
and, critically, in addressing each of these issues, we examine how the rising age of TBI patients in the ICU
might require new evidence to strengthen clinical management. 
Heterogeneity in pathology and pathophysiology 
Primary and secondary injury
TBI is classically divided into two distinct phases: a primary injury, followed by a delayed secondary injury. 
Primary injury arises from forces producing skull fractures, hematomas, and deformation and destruction of
brain tissue, including contusions and diffuse axonal injury. Cell membranes are stretched, dysregulating
trans-membrane ion fluxes, and impairing axonal transport. Secondary injury9,10 develops over time, with the
activation  of  multiple  molecular  pathways,  including  excitotoxicity  due  to  glutamate  accumulation,
activation of reactive oxygen species, ion channel and gap junction signaling, purinergic receptor signaling,
intracellular calcium accumulation, and mitochondrial dysfunction. All these phenomena may damage the
brain,  from  reversible  disturbances  up  to  necrosis  or  apoptosis.  They  may  also  be  responsible  for  the
development  of  cytotoxic  or  vasogenic  brain edema and disturbed autoregulation,  where the  volume of
intracranial contents increases because of vascular dilation and/or water accumulation 11. Once this volume
increase exceeds the compensatory capacities  of  the  intracranial  space,  intracranial  pressure (ICP) rises.
Early seizures may exacerbate the imbalance between energy expenditure and supply 12. Another electrical
disturbance, spreading depolarization, has recently been attracting more attention. Spreading depolarization
waves may occur in severe TBI patients and cause elevations in extracellular glutamate, increased anaerobic
metabolism, and energy substrate depletion. They also seem associated with worse outcome13. Inflammation
plays  an  important  role,  with  the  interplay  of  central  nervous  system  resident  or  peripherally-derived
inflammatory cells. Inflammation may provide neuroprotection or aggravate secondary injury 14. Patients with
TBI often suffer extra-cranial injuries (e.g. fractures, chest, and abdominal trauma) and massive bleeding.
These may cause hypoxia or arterial hypotension and trigger a systemic inflammatory response syndrome
that can further aggravate the development of secondary injury15.
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Figure 1 summarizes the main pathophysiological changes following TBI and their dynamic progression
over time.
Heterogeneity of TBI
TBI is often classified according to clinical severity, with severe TBI usually categorized on the basis of a
total Glasgow Coma Scale (GCS) score of 8 or less17.  TBI produces a spectrum of lesions that range from
mild injury to devastating damage. Expanding hematomas, extradural or subdural, may require emergency
surgical removal in the first hours after injury; intraparenchymal contusions may increase over hours or days
and require surgery as well. More subtle lesions such as traumatic axonal injury (TAI; the term commonly
used for diffuse axonal injury [DAI] only strictly applies when involving three or more locations18) may not
be evident from initial computed tomography (CT) scans but, due to the neuronal network disruption, it may
have a heavy effect on the quality of life of survivors, and is disclosed by magnetic resonance imaging
(MRI)19.  These different  lesion types  often occur  in  combination:  for  instance,  cerebral  contusions may
develop underneath a subdural hematoma, and may also be associated with axonal injury. Figure 2 shows
how the outcome, and the risk of high ICP, can vary by lesion type.
A  number  of  serum  and  CSF  biomarkers  of  neuronal  (neuron-specific  enolase;  ubiquitin  C-terminal
hydrolase L1; spectrin breakdown products),  axonal  (τ protein;  neurofilaments) and glial  (glial fibrillary
acidic  protein;  S100β)  injury  are  currently  being  investigated  in  TBI  patients24,25 and  could,  either
individually  or  in  concert,  be  used  to  characterize  injury  severity  and  type  and  may  have  prognostic
significance24,25. While preliminary evidence of cost effectiveness is emerging for some biomarkers in mild
TBI, their role in more severe TBI remains uncertain.  We need large-scale studies of the most promising
biomarkers (or panels of biomarkers) to demonstrate that they can be used to refine initial characterization of
brain damage in critically ill patients with TBI. 
Specific features of TBI in the elderly 
TBI in older  patients  often results  from low-energy impacts  such as  ground level  falls26,  with a  higher
proportion of  subdural  hematomas and less  contusions or epidural  hematomas27,28.  Cerebral  atrophy and
increased CSF space may buffer  new pathological  intracranial  masses,  with a lower incidence of raised
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ICP29,30,  and the  GCS may underestimate  the  severity  of  brain  injury31,  making a  case  for  higher  GCS
thresholds to trigger the triage of older patients to specialist centers32.  Further, age-related co-morbidities
(e.g. diabetes,  chronic cardiorespiratory disease, and renal  dysfunction) reduce physiological reserve and
increase the incidence and severity of brain damage due to second insults, such as hypoxia and hypotension.
Many of the therapies used for these chronic diseases (in particular, anticoagulants and antiplatelet agents)
may predispose to an increased incidence of  hemorrhage or  may worsen the evolution of intra-cerebral
traumatic lesions (with the greatest risk from vitamin K antagonists)33.  Finally, the diminished brain reserve
in these patients34 limits the potential for plasticity and neural repair, and hence hampers the success of
rehabilitation. The main differences between young and older TBI patients are listed in Panel 1. 
Fundamentals of ICU monitoring and management
Patients with severe TBI are currently treated in the ICU combining strategies used in general intensive care
(such as early enteral feeding; infection control and treatment; normalization of respiratory exchanges, with
skilled  nursing,  physiotherapy,  and  artificial  ventilation;  fluid  optimization  for  arterial  pressure  and
splanchnic organ perfusion,  etc.)  and a specialized neuro-intensive approach.  This aims at prevention of
second  insults  and  maintenance  of  cerebral  homeostasis.  Some  current  strategies  involve  targeted
approaches, such as surgical hematoma removal, whereas many medical therapies (for instance treatments
for controlling high ICP) are prescribed for all cases.
Prevention of second insults 
Prevention  of  second  insults  deals  both  with  systemic  (as  hypoxia,  hypercapnia,  arterial  hypotension,
hyponatremia, pyrexia, etc.) and intracranial threats (such as expanding hematomas or contusions, ICP rises,
etc.). Here, we focus on detection of intracranial threats through clinical examination and ICP monitoring.
Neurological clinical examination: Clinical examination remains a fundamental monitoring tool, even in the
comatose  or  sedated  patient  to  identify  neurological  deterioration  and potential  indications  for  surgical
interventions. The basic examination relies on a GCS evaluation coupled with assessment of pupil diameter
and reactivity to light. There are some obstacles to a complete GCS assessment: tracheal intubation precludes
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a  verbal  response  and  facial  injuries  may  impede  eye  opening,  so  motor  response  remains  the  main
assessable component of the GCS score. Neurological evaluation in deeply sedated patients may require a
sedation  hold  (wake-up  test),  which  may  cause  arterial  hypertension  and,  in  patients  with  reduced
intracranial compliance, transient ICP rises45. It is currently debated whether these ICP spikes are detrimental
for brain homeostasis or not46,47. 
On  the  other  hand,  a  wake-up test  may identify  important  clinical  changes,  in  cases  showing signs  of
progressive brain stem impairment or in those with rapid improvement, as after successful surgical removal
of intracranial masses and patients with alcohol or other intoxications. This may profoundly influence their
management, with more aggressive intervention in case of deterioration or shorter intubation and ventilation
times in cases evolving favorably.
Pupillary diameter and reactivity are vital48. A dilated, unreactive pupil usually discloses compression of the
third  cranial  nerve due to  midline  shift  and uncal  herniation49.  Pupillary reaction  to  light  is  commonly
assessed using a flashlight which, however, has poor inter-rater accuracy in clinical practice 50. Automated
pupillometry is a portable technique that measures pupil size and light reactivity  automatically, and with a
high degree of precision51. It may give more accurate measurements of reactivity, especially when the pupil
is small, as with opioid analgesia 51.
Up to 40% of patients52 experience significant worsening during the first 48 hours in the ICU. Neurological
worsening is currently defined as 1) a decrease of 2 points of the GCS motor component,  or 2) loss of
pupillary reactivity  or  asymmetry, or  3)  deterioration  in  neurological  or  CT status  sufficient  to  warrant
immediate medical or surgical intervention18. Neuroworsening in TBI is significantly associated with high
ICP and poor outcome53,54.  This is often due to a new or expanding intracranial  lesion that  may require
surgical evacuation. This progression is becoming increasingly important because prompt access to early CT
means that patients are often scanned within minutes after the TBI, before lesions had a chance to appear or
evolve. Parenchymal lesions may evolve in hours to days: in a series of 352 cases with contusions followed
up with three CT scans, the volume of hemorrhage increased in 42% of patients55. A routine second CT scan
is therefore recommended for all comatose TBI patients, where it may disclose surgical lesions in up to one
third of cases56. Additionally, if there is any substantial clinical worsening and/or ICP elevation, a new CT
scan must be performed56. 
7
ICP monitoring: ICP measurement is performed through ventricular or intraparenchymal probes connected to
monitor11.  This  monitoring has  been the cornerstone of  TBI care  since the 1980s,  although it  has  been
questioned recently in a multicenter trial (BEST:TRIP) in South America, where ICU management based on
repeated  clinical  examination  and  CT  scans  was  not  inferior  to  management  including  continuous
measurement of ICP57. It would be entirely inappropriate to discard the role of ICP monitoring based on this
study58, but it does illustrate the fact that postulating a direct link from monitoring to improving outcome is
too simplistic when considered in isolation. 
In  the  latest  edition  of  the  Brain  Trauma Foundation  (BTF)  guidelines,  ICP monitoring  is  indicated  in
patients with severe TBI, because evidence suggests that ICP-guided treatment may reduce early mortality 4.
A variable proportion of severe TBI patients develops raised ICP, often depending on the definition. The
historical and most widely accepted ICP threshold for therapy is 20 mmHg, though recent guidelines suggest
22 mmHg4.  This approach,  which is  based on population targets,  provides little potential  for  optimizing
therapy based on the needs of individual patients.  Indeed, the available literature suggests that there may be
subtle differences in critical ICP thresholds between young and old patients and males and females, even at
an  aggregated  population  level,  with  older  patients  (>55  years  of  age)  and  females  having  lower  ICP
thresholds (18 vs. 22 mmHg) for prediction of poor outcome59.  
Protocols for ICP therapy vary in detail but generally include the prevention of ICP rises, with mechanical
ventilation, sedation, and avoidance of pyrexia, as well as active interventions11. For ICP elevations, first-tier
strategies include edema management with hyperosmotic infusions and CSF drainage (when a ventricular
drain  is  available).  More  aggressive  therapies  are  required  for  refractory  ICP, including  hypothermia,
metabolic suppression with deep sedation, decompressive craniectomy, and hypocapnia, but these have more
harmful  side effects,  as illustrated in Figure 3 (and discussed below).  ICP monitoring is  relatively safe;
complications  (hemorrhage  and  infection)  arise  in  1-7%  of  cases62,  driving  a  search  for  non-invasive
alternatives. Several methods are under investigation for non-invasive ICP measurement, but are not ready
for clinical use yet11.  
Maintenance of cerebral homeostasis
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Maintenance of cerebral homeostasis and, in particular, optimization of cerebral oxygen supply and demand,
is traditionally attempted using indirect parameters such as cerebral perfusion pressure (CPP), the difference
between mean arterial blood pressure (ABP) and ICP. Ideally a normal arterial pressure, coupled with a
physiological ICP value, should be maintained. In case of arterial hypotension, vasopressors and volume
expansion are used to restore an adequate arterial pressure, while ICP becomes a target when it exceeds a
threshold (see above). CPP around 60 mmHg is generally targeted, though the latest guidelines suggest some
discrimination  between  individuals  with  and without  preserved autoregulation4,  but,  as  for  ICP, do  not
account for differences in CPP thresholds between patient groups59. 
Modulatory influences of age
There is a clear association between older age and worse outcome42,43, which might be explained, at least in
part,  by  the  effects  of  age-related  co-morbidities63,  use  of  pharmacotherapies  to  treat  comorbidities
(especially antithrombotic drugs39), and reduced brain reserve in elderly patients34.  Care of comorbidities
may therefore be as important as management of TBI in determining outcome 63. Treatment of drug-induced
coagulopathy in particular is essential64,65 with reversal of anticoagulant and antiplatelet therapy if there is
significant hemorrhage65.  Post-traumatic seizures are common in older TBI patients40; however, the optimal
therapy and length of seizure prophylaxis in this population is still not clear.
Unfavorable outcome in older patients could be, at least in part, a self-fulfilling prophecy. Data collected on
4387 TBI patients in the UK indicates suboptimal care for older patients (including delayed CT scans),
assessment  by more junior  medical  staff,  and a  reduced likelihood of  being transferred to  neurotrauma
centers44.  However, when older patients are treated aggressively and promptly following ICU admission,
favorable outcomes are seen in 39% of patients between the ages of 60 and 69 years 27, suggesting that this
nihilistic attitude is not justified. 
The lower ICP thresholds (18 mmHg vs. 22 mmHg)59 associated with poor outcome in older patients might
reflect the greater vulnerability of the aged brain, or a given ICP elevation may denote a worse brain injury in
older patients, since age related atrophy allows space lesion expansion and brain edema before ICP rises.
Notwithstanding the cause, these data make a case for exploring whether a reduced threshold for ICP control
might be beneficial in the older patient. However, since elevated ICP is less frequent in the elderly and tissue
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penetration by intracranial probes is riskier in patients with anticoagulant and antiplatelet therapy, there is a
case for revised (reduced) indications for ICP monitoring in these patients.  Elderly patients may also have
compromised autoregulation because of arterial hypertension, with the autoregulatory curve shifted toward
higher arterial pressures.  Indeed, the available59 data suggest that CPP thresholds for survival are higher in
patients  over  the  age  of  55  years  (75  vs  70  mmHg),  suggesting  that  a  higher  CPP may be  desirable,
particularly in patients with a history of arterial hypertension4,59. 
It  is  worth noting that  the current  conceptual  basis  of  ICU management  of  TBI is  based on a body of
experience accumulated over the last four decades, which overwhelmingly derives from younger patients,
with high velocity injuries.  It would be wrong, or at least unsafe, to assume that this experience can be
directly applied to the older patients we now see with different injury mechanisms, and there is a pressing
need to develop optimum management strategies targeted to these patients.
Targeted ICU management: the role of physiological monitoring
Clinical TBI pathophysiology is host-, treatment- and injury-dependent and therefore highly heterogeneous.
A  “one  size  fits  all”  management  strategy  is  unlikely  to  be  optimal.  More  precise  understanding  of
intracranial disturbances might indicate specific targets and, hopefully, targeted therapies. 
A panoply of monitoring techniques and imaging modalities have been employed to achieve this information,
including measurement of brain tissue partial tension of oxygen (PbtO2), microdialysis, and autoregulation
assessment (Table 1). In isolation, these techniques are at best indirect surrogates for a complex condition in
our most complex organ. For example, raised ICP is not a diagnosis by itself. It results from many (often
coexisting) mechanisms, including edema (either cytotoxic or vasogenic), increased cerebral blood volume
(which  itself  may  result  from  many  disparate  mechanisms  including  excessive  metabolic  demand,
hypercapnia, or disordered autoregulation, to name but a few), or impaired CSF reabsorption. Tools for better
characterization of pathophysiological derangements have been available in the last two decades; however,
they have been rarely used even in the most specialized neuro ICU. A recent survey of monitoring modalities
in 31 UK specialized ICUs found that ICP was commonly used in all but one institution, PbtO2 in 26% and
microdialysis only in 13%67. 
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Brain tissue partial tension of oxygen measurement 
ICP and CPP provide information on the driving pressure for blood flow through the cerebral circulation.
However, downstream metabolic event can also be monitored using several probes, often through a common
insertion  device.  One  such example  is  the  measurement  of  PbtO2  based  on  seminal  studies  of  pioneer
European groups68-70. This provides a continuous (albeit localized) spatial average of extracellular oxygen
tension as an indicator of the adequacy of oxygen delivery. PbtO2 depends on the balance between oxygen
delivery and consumption, and the cerebral metabolic rate of oxygen (CMRO2). It is further influenced by
the oxygen’s ability to diffuse71,72. For example, in pericontusional tissue this may be influenced not only by
tissue and endothelial edema, but also by microvascular collapse which increases the mean inter-capillary
distance for diffusion, reducing average oxygen tension72. 
Determining appropriate target values for PbtO2 is clearly methodologically difficult: oxygen tensions around
23 mmHg are recorded during/after functional neurosurgery73. Values between 15 and 20 mmHg are typically
regarded as thresholds for inadequate oxygen supply74-76 and are associated with worse outcome after TBI72.
Therapeutic  approaches  aimed at  normalization of  PbtO2,  either  by increasing arterial  pressure  and /or
arterial  oxygen tension,  have  been  published77,78.  Those  strategies  seem to  obtain  better  outcomes  than
strategies only focused on ICP and CPP. However, in absence of large, controlled trials,  evidence at the
moment is inconclusive79.
Microdialysis 
Measurement of glucose, lactate and pyruvate in the brain extracellular space using cerebral microdialysis
provides information on energy metabolism. A high lactate/pyruvate ratio (LPR) after TBI is a marker of
anaerobic  glucose utilization,  resulting from low PbtO2 due  to  ischemia or  diffusion hypoxia  or,  under
normoxic conditions as a consequence of mitochondrial dysfunction80-82.  A high LPR indicates an energy
metabolism crisis and is an independent predictor of mortality83. Improvement of the LPR may indicate a
beneficial effect of treatment. Various interventions, like hyperoxia and hypertonic lactate, have been tested
on  the  brain  energy  metabolism.  Normobaric  hyperoxia,  usually  induced  by  increasing  the  fraction  of
inspired  oxygen  (FiO2),  can  normally  raise  a  low  PbtO2,  but  shows  variable  benefit  on  microdialysis
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parameters in different studies84,85, though imaging studies suggest improvements in CMRO286 and reversal of
pericontusional  cytotoxic  edema87.  Attempts  to  improve brain glucose metabolism by hypertonic  lactate
infusions show a clear cerebral glucose-sparing effect,  but mainly in patients with a pathological LPR 88.
These preliminary clinical  trials  require  larger  numbers  for  confirmation,  but  indicate  the  possibility  of
targeted interventions.
Autoregulation assessment
One area that has received attention is  on-line real-time assessment of cerebrovascular autoregulation,  a
physiological  mechanism that  serves  to  maintain  adequate  cerebral  perfusion  in  the  presence  of  blood
pressure changes66. Under normal conditions, with a normal autoregulation, the diameter of cerebral vessels
changes to adjust for arterial pressure alterations (vasoconstriction in response to arterial hypertension, for
instance), and these changes may impact ICP. In case of vasoconstriction ICP should remain unaffected or it
may decrease.  ICP may be therefore  used for  assessing how the brain vessels  react  to arterial  pressure
variation. In pathological conditions, as severe TBI, autoregulation can be altered or totally lost. Probably the
measurement best known is the pressure-reactivity index (PRx): the correlation coefficient between samples
of  ICP  and  arterial  pressure  using  a  moving  data  window,  which  is  normally  a  negative  number 89-91.
Furthermore, PRx often shows a U-shaped relationship when plotted against spontaneous changes in CPP
over time, with the lowest PRx observed in the optimal autoregulatory range. The CPP for which PRx is a
minimum is therefore felt to represent a state of optimal autoregulation, and management close to this has
been associated with better outcomes92,93. An autoregulation-guided approach to individualize CPP may be
helpful in preventing cerebral hypoperfusion while at the same time avoiding the risks of excessive CBF. An
approach  based  on  optimization  of  autoregulation  is  physiologically  attractive  and  has  the  potential  to
reconcile perfusion-supporting and edema-minimizing treatments. However, autoregulation may be impaired
in a region-specific way which may not be captured by PRx, which is a global average. Alternative measures
based on assessment of blood flow or brain tissue oxygen reactivity suffer the opposite limitation of limited
global  spatial  coverage.  Prospective evidence from clinical  studies is  urgently required before definitive
guidelines can be drawn up.
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Multimodal monitoring for tailoring therapies
There  is  consensus66  that  simultaneous  use  of  several  monitoring  modalities  may  provide  a  means  of
targeting  patient  specific  ICP thresholds.  Concordant  changes  documented  by  different  sources  provide
cross-validation of physiology in the injured brain. For example, a critical PbtO2 reduction may be used to
individualize thresholds for more aggressive methods for correcting low CPP due to high ICP. Conversely,
discordant findings,  while potentially posing a clinical dilemma in terms of treatment compromise, may
sometimes offer clues to the presence of pathophysiological heterogeneity and stimulate the search for less
well-recognized routes to energy failure, such as diffusion hypoxia71,72, mitochondrial dysfunction94, and low
cerebral glucose levels83,95 as downstream markers of compromised cerebral perfusion . 
However, current  multimodality neuromonitoring generates vast  amounts of data which may need to be
summarized for clinicians to extract information that can be used to guide patient care (Figure 4). Advances
in  monitoring  will  probably  also  require  advances  in  neuroinformatics  and  data  analysis96.  Computer
visualization  techniques  offer  one  promising  way  to  reduce  complex  datasets  to  a  form  that  can  be
interpreted by a human, and have been applied in various areas including assessment of the cumulative
burden  of  intracranial  hypertension97  and  autoregulation  assessment98.  Such  complex  multidimensional
problems are not new outside medicine, and other techniques from the field of ‘big data’ will very likely find
increasing application in the intensive care of TBI patients99. 
Physiological monitoring in the elderly
 The use of advanced multimodality monitoring to guide therapy in older patients is conceptually appealing,
but experience in this area is limited. This lack of experience is in part explained by increased risks of
invasive intracranial monitoring in older patients who commonly present on anticoagulants and anti-platelet
therapies, and in part by the expectation of poor outcome that has made aggressive monitoring and therapy
less frequent in this age group.  Changing attitudes may provide more data to guide therapy individualization
for older patients in the future, and development of less invasive monitoring tools would be particularly
beneficial in this group.
Targeted ICU management with aggressive therapies 
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None of our therapies in the ICU are risk free, and the more aggressive interventions for restoring cerebral
homeostasis  have  substantial  potential  to  cause  harm.   Multimodal  monitoring  can  demonstrate  that
aggressive interventions are justified,  by proving that  cerebrovascular physiology (ICP and CPP outside
thresholds,  and/or  PbtO2 reductions  and  elevations  in  lactate  and  lactate/pyruvate  ratio)  is  seriously
compromised, and not amenable to therapy with less risky interventions.  Once a therapeutic target has been
identified, for some interventions, careful measurement of physiological variables may minimize harm. 
CPP augmentation
Pharmacological augmentation of CPP may improve cerebral oxygenation but at the expense of serious 
cardiopulmonary complications100.  Advanced cardiovascular monitoring, including intravascular volume 
assessment, echocardiography, cardiac output etc. beyond standard pulse oximetry and invasive arterial 
pressure monitoring, may be necessary66.
Hypocapnia
Brief period of hypocapnia may be justifiable in the face of an episode of menacingly high ICP but it may 
cause dangerous ischemia through vasoconstriction101, especially in the early phases after injury. For this 
reason, measurement of cerebral oxygenation, most commonly using PbtO2 monitoring, is recommended 
when hypocapnia is used, to minimize the ischemic risk66.
Metabolic suppression
Barbiturates  for  metabolic  suppression  are  effective  in  reducing  ICP  but  carry  significant  risks  of
cardiovascular  instability  and  other  end-organ  dysfunction  or  metabolic  disturbances102.  Advanced
cardiovascular monitoring and support (including fluid titration, inotropes, and vasopressors) is advisable to
avoid arterial hypotension. 
Hypothermia
Hypothermia, a treatment with strong neuroprotective action in animal models103, failed to show outcome
benefit  in  clinical  trials61.  When,  recently, moderate  hypothermia  (32  to  35°C) was  used  as  early  ICP
intervention,  the  treated  group  had  a  worse  outcome  than  controls61.   Despite  the  results  of  this  trial,
hypothermia continues to be used in some centers, but often with higher ICP thresholds (25-30 mmHg)104,
denoting an implicit acceptance that the risks of hypothermia demand more deranged physiology before the
risk-benefit ratio becomes favorable. 
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Decompressive craniectomy
Decompressive craniectomy (DC) is effective in reducing ICP, but results of RCTs have shown differences in
outcome depending on the target group. The DECRA trial showed that it did not improve outcome when
used for modest ICP increases60. However, the balance of risk and benefit changes in circumstances where
aggressive therapies are justified by the presence of refractory severe intracranial hypertension. For example,
the RESCUE-ICP105 study showed that DC targeted to patients with refractory severe ICP reduced mortality,
and shifted neurological  outcomes so that  more patients  could at  least  function independently at  home,
although these gains were achieved at the expense of increases in survival with severe disability. 
These findings emphasize the importance of following a graded sequence for these aggressive interventions,
beginning with those with least potential for harm before escalating to higher - and potentially more harmful
- therapeutic intensity (see Figure 2). Furthermore, the evidence highlights the need to select interventions
based on the clinical picture in individual patients, and the circumstances at the time of intervention. Further
research  into  the  contribution  of  the  physiological  monitoring  methods  might  enable  more  refined
stratification of patients for these more aggressive therapies.
Aggressive therapies in elderly patients
Aggressive therapies are linked to severe side-effects, and might not be tolerated by frail old patients with
impaired physiological reserve. The high incidence of cardiorespiratory comorbidities in such individuals
might further reduce the ability of patients to tolerate some of the aggressive interventions (such as CPP
augmentation, barbiturates, and hypothermia) used in the critical care of TBI. Therefore, careful monitoring
of systemic physiology is mandatory, and  caution is needed with hemodynamic augmentation and second
stage therapies for high ICP in these patients. 
The two major RCTs60,105 on DC for TBI excluded patients older than 65 years,  probably reflecting the
skepticism of the neurotrauma community against extreme therapies in the elderly. Another study, where DC
was used for the treatment of unilateral or bilateral brain swelling in 44 TBI patients over the age of 66 years,
resulted in 77% mortality and 82% overall unfavorable outcomes, leading to this approach being abandoned
in clinical practice for elderly patients who present with a GCS < 8106. 
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Emerging opportunities in management of severe TBI 
The focus of this review has been on how we might improve clinical management of TBI using techniques 
that are already available, even if not widely used in clinical practice. However, emerging advances could 
deliver additional refinement, or even paradigm changes, in how we treat these patients, with regard to better
characterization, identification of novel therapeutic targets, and the generation of evidence to support 
changes in management. The failure of four recent pharmacological trials, two on erythropoietin107,108 and 
two on progesterone109,110, to improve neurological outcome despite experimental evidence of multiple 
neuroprotective mechanisms underlines the importance of targeting treatments to selected patient groups. 
Enrolment criteria in these trials were based on TBI severity, and the benefits of compounds acting on 
specific pathways may not have been demonstrable in a heterogeneous population of TBI patients. Future 
trials should aim to select patients on the basis of specific mechanisms of brain damage in individual patients
to maximize potential for improved outcomes.
The growing use of magnetic resonance imaging in TBI promises to provide better definitions of injury 
location, type and severity111, and accumulating data linking genetic variability to outcome112 suggests that it 
may prove possible identify patients in whom specific therapies could be effective. For instance, once the 
pathological role of spreading depression is clarified better, specific interventions -such as nimodipine or 
ketamine - could be envisaged to correct it113. Promising new therapeutic targets are emerging from more 
rigorous preclinical evaluation of new interventions in TBI, such as those delivered by Operation Brain 
Trauma Therapy, a multicenter, multiplatform collaboration for experimental evaluation of new therapies114. 
Other basic biology that may rapidly translate to clinical intervention includes the sulphonylurea receptor 
(SUR1) which is implicated in edema formation and contusion expansion115, novel brain fuels that bypass 
identified blocks in energy generation116, more precise action on the host immune response117 (which is 
emerging as a key player in pathophysiology), and characterizing the acute pathophysiological role of 
neurodegenerative processes such as amyloid, which are now clinically detectable hours to days following 
TBI118. 
Conclusions
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Advances in monitoring provide a paradigm that could enable the ICU care of TBI to move from a standard
“one size fits all” approach to more individualized treatment. Better identification of mechanisms as potential
targets for  intervention seems a reasonable  aspiration.  Improved characterization of disease mechanisms
might  also offer  new goals for neuroprotective drug development. But the translational  failure of a few
biologically and experimentally well-founded interventions119 suggests that uncharacterized patient factors
are  still  a  major  stumbling  block  in  terms  of  tailoring  aggressive  treatments  to  maximize  benefit  and
minimize harm at an individual level. Despite the wealth of data, the stratification of patients into subgroups
with more homogeneous pathophysiology, disease course and expected outcome is still at an early stage. 
The integration of newer monitoring modalities can provide more individualization of therapy, but these
approaches are  based on data  that  do not  come from directly  targeted RCTs.   Indeed,  the  results57 and
subsequent  discussion58 of  the  BEST:TRIP  trial  highlight  the  difficulties  with  using  classical  RCTs to
evaluate monitoring devices and treatment thresholds, and we may need to rely on other means of evidence
generation, such as comparative effectiveness research (CER), to provide strong frameworks for use of these
devices.  Such  approaches  will  require  large,  well  characterized  populations  of  patients,  with  rigorous
outcome assessment. International initiatives such as the Collaborative European NeuroTrauma Effectiveness
Research in TBI (CENTER-TBI,  https://www.center-tbi.eu) and other partner studies in the International
Traumatic Brain Injury Research initiative (InTBIR, https://intbir.nih.gov/) could provide the large samples
needed  to  address  this  aim,  and  provide  the  substrate  for  developing  and  testing  precision-medicine
approaches in severe TBI. 
The epidemiological shift towards a larger proportion of physiologically fragile elderly patients with TBI in
HICs calls for varying preventive approaches, such as measures aimed at frailty and falls 120, and suggests the
need for changes in ICU management approaches. Less invasive monitoring tools, for instance, may improve
care  and  reduce  side  effects  during  the  acute  phase.  Methods  for  quick  and  efficient  restoration  of
coagulation may limit  brain injury progression in patients on anticoagulant  and antiplatelet  agents,  thus
improving outcomes. Provision of care based on measured, rather than assumed, outcome could avoid self-
fulfilling prophecies of inevitable poor outcome for older patients. Age older than 65 years has often been an
exclusion  criterion  in  clinical  trials  of  interventions  for  TBI,  such  as  DC  and  of  neuroprotective
drugs52,60,105,108,121,  leading to the paradox that a population segment at increased risk of TBI has not been
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exposed to possible therapeutical interventions. Given the logistic complexities of conducting RCTs in TBI
generally and specifically in the older patient population, CER approaches might also facilitate assessment of
interventions  in  older  patients,  with  differences  in  management  of  these  patients  in  different  centers
providing an appropriate context to undertake such studies.
The  changes  described  here  hold  the  promise  of  reshaping  current  ICU  management,  and  potentially
improving outcome. However, demonstration that this promise can be fulfilled requires rigorous research
evaluation and proof of cost-effectiveness.
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